Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2011 Feb 22;76(8):693-700.
doi: 10.1212/WNL.0b013e31820d8b0b.

Antiretroviral therapy CNS penetration and HIV-1-associated CNS disease

L Garvey  1 , A Winston, J Walsh, F Post, K Porter, B Gazzard, M Fisher, C Leen, D Pillay, T Hill, M Johnson, R Gilson, J Anderson, P Easterbrook, L Bansi, C Orkin, J Ainsworth, A Palfreeman, M Gompels, A N Phillips, C A Sabin; UK Collaborative HIV Cohort (CHIC) study
Affiliations

Antiretroviral therapy CNS penetration and HIV-1-associated CNS disease

L Garvey et al. Neurology. .

Abstract

Objective: The impact of different antiretroviral agents on the risk of developing or surviving CNS disease remains unknown. The aim of this study was to investigate whether using antiretroviral regimens with higher CNS penetration effectiveness (CPE) scores was associated with reduced incidence of CNS disease and improved survival in the UK Collaborative HIV Cohort (CHIC) Study.

Methods: Adults without previous CNS disease, who commenced combination antiretroviral therapy (cART) between 1996 and 2008, were included (n = 22,356). Initial and most recent cART CPE scores were calculated. CNS diseases were HIV encephalopathy (HIVe), progressive multifocal leukoencephalopathy (PML), cerebral toxoplasmosis (TOXO), and cryptococcal meningitis (CRYPTO). Incidence rates and overall survival were stratified by CPE score. A multivariable Poisson regression model was used to identify independent associations.

Results: The median (interquartile range) CPE score for initial cART regimen increased from 7 (5-8) in 1996-1997 to 9 (8-10) in 2000-2001 and subsequently declined to 6 (7-8) in 2006-2008. Differences in gender, HIV acquisition risk group, and ethnicity existed between CPE score strata. A total of 251 subjects were diagnosed with a CNS disease (HIVe 80; TOXO 59; CRYPTO 56; PML 54). CNS diseases occurred more frequently in subjects prescribed regimens with CPE scores ≤ 4, and less frequently in those with scores ≥ 10; however, these differences were nonsignificant. Initial and most recent cART CPE scores ≤ 4 were independently associated with increased risk of death.

Conclusion: Clinical status at time of commencing cART influences antiretroviral selection and CPE score. This information should be considered when utilizing CPE scores for retrospective analyses.

PubMed Disclaimer

Figures

Figure
Figure. Rates of new CNS event
Rates of new CNS event (A) stratified by initial and most recent central nervous penetration effectiveness (CPE) scores (B). ART = antiretroviral treatment.
See this image and copyright information in PMC

References

    1. Mocroft AJ, Lundgren JD, d'Armino Monforte A, et al. Survival of AIDS patients according to type of AIDS-defining event: The AIDS in Europe Study Group. Int J Epidemiol 1997;26:400–407 - PubMed
    1. Fong IW, Toma E. The natural history of progressive multifocal leukoencephalopathy in patients with AIDS. Clin Infect Dis 1995;20:1305–1310 - PubMed
    1. Grabar S, Lanoy E, Allavena C, et al. , Clinical Epidemiology Group of the French Hospital Database on HIV Causes of the first AIDS-defining illness and subsequent survival before and after the advent of combined antiretroviral therapy. HIV Med 2008;9:246–256 - PubMed
    1. d'Arminio Monforte A, Cinque P, Mocroft A, et al. Changing incidence of central nervous system diseases in the EuroSIDA cohort. Ann Neurol 2004;55:320–328 - PubMed
    1. Varatharajan L, Thomas SA. The transport of anti-HIV drugs across blood-CNS interfaces: summary of current knowledge and recommendations for further research. Antiviral Res 2009;82:A99–109 - PMC - PubMed

Publication types

MeSH terms